U.S. Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Type (Systemic Autoimmune Disease Diagnostics, Localized Autoimmune Disease Diagnostics), By Test Type, By End-use, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 3 Business Days
U.S. Autoimmune Disease Diagnostics Market Growth & Trends
The U.S. autoimmune disease diagnostics market size is anticipated to reach USD 3.01 billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of autoimmune diseases and increasing technological advancements in diagnostic tools and techniques aresignificantly driving the growth of the market.
Increasing awareness about autoimmune diseases among healthcare professionals and patients has led to a higher rate of diagnosis and screening. Public health initiatives, educational campaigns, and advocacy efforts have raised awareness about the signs and symptoms of autoimmune diseases, prompting individuals to seek early diagnosis and treatment. Screening programs aimed at high-risk populations have also contributed to the early detection of autoimmune conditions.
The increasing healthcare expenditure globally, coupled with the growing burden of autoimmune diseases on healthcare systems, has fueled the demand for advanced diagnostic solutions. The government and private organizations are investing in healthcare infrastructure, research, and development to address the challenges posed by autoimmune diseases. This investment drives innovation in diagnostic technologies and promotes access to quality diagnostic services for patients with autoimmune conditions.
U.S. Autoimmune Disease Diagnostics Market Report Highlights
U.S. Autoimmune Disease Diagnostics Market Growth & Trends
The U.S. autoimmune disease diagnostics market size is anticipated to reach USD 3.01 billion by 2030, growing at a CAGR of 5.2% from 2024 to 2030, according to a new report by Grand View Research, Inc. The rising incidence of autoimmune diseases and increasing technological advancements in diagnostic tools and techniques aresignificantly driving the growth of the market.
Increasing awareness about autoimmune diseases among healthcare professionals and patients has led to a higher rate of diagnosis and screening. Public health initiatives, educational campaigns, and advocacy efforts have raised awareness about the signs and symptoms of autoimmune diseases, prompting individuals to seek early diagnosis and treatment. Screening programs aimed at high-risk populations have also contributed to the early detection of autoimmune conditions.
The increasing healthcare expenditure globally, coupled with the growing burden of autoimmune diseases on healthcare systems, has fueled the demand for advanced diagnostic solutions. The government and private organizations are investing in healthcare infrastructure, research, and development to address the challenges posed by autoimmune diseases. This investment drives innovation in diagnostic technologies and promotes access to quality diagnostic services for patients with autoimmune conditions.
U.S. Autoimmune Disease Diagnostics Market Report Highlights
- Localized autoimmune disease diagnostics type dominated the market with a 66.0% share in 2023 owing to the rising advanced imaging techniques, such as ultrasound, MRI, and PET scans, which allow for detailed visualization of affected tissues or organs.
- The antinuclear antibody test type segment held the largest market share in 2023 and is anticipated to witness the fastest growth over the forecast period.
- The hospitals end-use segment dominated the market in 2023 owing to the growingneed for accurate and precise testing methods.
- In November 2023, Progentec Diagnostics and Mayo Clinic Laboratories announced a strategic partnership to commercialize Progentec’s range of patented biomarker blood tests for the early detection and treatment of autoimmune disorders. The partnership seeks to improve accessibility for patients and clinicians in the United States and a few international markets.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Test Type
1.2.3. End-use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test outlook
2.2.2. Test type outlook
2.2.3. End-use outlook
2.3. Competitive Insights
CHAPTER 3. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Presence of research funding programs
3.2.1.2. Presence of favorable government initiatives
3.2.1.3. Growing patient awareness levels
3.2.1.4. Technological innovation in the form of lab automation
3.2.2. Market restraint analysis
3.2.2.1. Slow diagnostic result turnaround times and lack of skilled
3.3. U.S. Autoimmune Disease Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Autoimmune Disease Diagnostics Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. U.S. Autoimmune Disease Diagnostics
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Rheumatoid arthritis
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Ankylosing spondylitis diagnostics
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Systemic lupus erythematosus (SLE)
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Others
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Localized autoimmune disease diagnostics
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Multiple sclerosis
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Type 1 diabetes
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Hashimoto's Thyroiditis
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.5. Idiopathic thrombocytopenic purpura
4.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.6. Others
4.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
5.1. Test Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Autoimmune Disease Diagnostics Market by Test Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Antinuclear antibody tests
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Autoantibody tests
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. C-reactive Protein (CRP)
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Complete blood count (CBC)
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Urinalysis
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Others
5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. End-use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Autoimmune Disease Diagnostics Market by End-use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Hospitals
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Diagnostic centers
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: REGION ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share, 2023 & 2030
7.2. U.S. Autoimmune Disease Diagnostics Market by Region Outlook
7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
7.3.1. West
7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Midwest
7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Northeast
7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.4. Southwest
7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.5. Southeast
7.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company heat map analysis, 2023
8.4. Company Profiles
8.4.1. Medtronic
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Boston Scientific Corporation
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Johnson & Johnson Service Inc. (Ethicon, Inc.)
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. AngioDynamics
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Bioventus Inc. (Misonix Inc.)
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. EDAP TMS
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Chongqing Haifu Medical Technology Co., Ltd
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Mermaid Medical
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. HealthTronics, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. H.S. Hospital Service S.p.A.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Type
1.2.2. Test Type
1.2.3. End-use
1.2.4. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Volume price analysis (Model 2)
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Test outlook
2.2.2. Test type outlook
2.2.3. End-use outlook
2.3. Competitive Insights
CHAPTER 3. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Presence of research funding programs
3.2.1.2. Presence of favorable government initiatives
3.2.1.3. Growing patient awareness levels
3.2.1.4. Technological innovation in the form of lab automation
3.2.2. Market restraint analysis
3.2.2.1. Slow diagnostic result turnaround times and lack of skilled
3.3. U.S. Autoimmune Disease Diagnostics Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
CHAPTER 4. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: TYPE ESTIMATES & TREND ANALYSIS
4.1. Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. U.S. Autoimmune Disease Diagnostics Market by Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
4.4.1. U.S. Autoimmune Disease Diagnostics
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.2. Rheumatoid arthritis
4.4.1.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.3. Ankylosing spondylitis diagnostics
4.4.1.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.4. Systemic lupus erythematosus (SLE)
4.4.1.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.1.5. Others
4.4.1.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Localized autoimmune disease diagnostics
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.2. Multiple sclerosis
4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.3. Type 1 diabetes
4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.4. Hashimoto's Thyroiditis
4.4.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.5. Idiopathic thrombocytopenic purpura
4.4.2.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2.6. Others
4.4.2.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: TEST TYPE ESTIMATES & TREND ANALYSIS
5.1. Test Type Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. U.S. Autoimmune Disease Diagnostics Market by Test Type Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
5.4.1. Antinuclear antibody tests
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Autoantibody tests
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.3. C-reactive Protein (CRP)
5.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.4. Complete blood count (CBC)
5.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.5. Urinalysis
5.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.6. Others
5.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: END-USE ESTIMATES & TREND ANALYSIS
6.1. End-use Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. U.S. Autoimmune Disease Diagnostics Market by End-use Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
6.4.1. Hospitals
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Diagnostic centers
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Others
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. U.S. AUTOIMMUNE DISEASE DIAGNOSTICS MARKET: REGION ESTIMATES & TREND ANALYSIS
7.1. Regional Market Share, 2023 & 2030
7.2. U.S. Autoimmune Disease Diagnostics Market by Region Outlook
7.3. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the Following
7.3.1. West
7.3.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.2. Midwest
7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.3. Northeast
7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.4. Southwest
7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
7.3.5. Southeast
7.3.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. COMPETITIVE LANDSCAPE
8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Company/Competition Categorization
8.3. Vendor Landscape
8.3.1. List of key distributors and channel partners
8.3.2. Key customers
8.3.3. Key company heat map analysis, 2023
8.4. Company Profiles
8.4.1. Medtronic
8.4.1.1. Company overview
8.4.1.2. Financial performance
8.4.1.3. Product benchmarking
8.4.1.4. Strategic initiatives
8.4.2. Boston Scientific Corporation
8.4.2.1. Company overview
8.4.2.2. Financial performance
8.4.2.3. Product benchmarking
8.4.2.4. Strategic initiatives
8.4.3. Johnson & Johnson Service Inc. (Ethicon, Inc.)
8.4.3.1. Company overview
8.4.3.2. Financial performance
8.4.3.3. Product benchmarking
8.4.3.4. Strategic initiatives
8.4.4. AngioDynamics
8.4.4.1. Company overview
8.4.4.2. Financial performance
8.4.4.3. Product benchmarking
8.4.4.4. Strategic initiatives
8.4.5. Bioventus Inc. (Misonix Inc.)
8.4.5.1. Company overview
8.4.5.2. Financial performance
8.4.5.3. Product benchmarking
8.4.5.4. Strategic initiatives
8.4.6. EDAP TMS
8.4.6.1. Company overview
8.4.6.2. Financial performance
8.4.6.3. Product benchmarking
8.4.6.4. Strategic initiatives
8.4.7. Chongqing Haifu Medical Technology Co., Ltd
8.4.7.1. Company overview
8.4.7.2. Financial performance
8.4.7.3. Product benchmarking
8.4.7.4. Strategic initiatives
8.4.8. Mermaid Medical
8.4.8.1. Company overview
8.4.8.2. Financial performance
8.4.8.3. Product benchmarking
8.4.8.4. Strategic initiatives
8.4.9. HealthTronics, Inc.
8.4.9.1. Company overview
8.4.9.2. Financial performance
8.4.9.3. Product benchmarking
8.4.9.4. Strategic initiatives
8.4.10. H.S. Hospital Service S.p.A.
8.4.10.1. Company overview
8.4.10.2. Financial performance
8.4.10.3. Product benchmarking
8.4.10.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 U.S. autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. autoimmune disease diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 4 U.S. systemic autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
Table 5 U.S. localized autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
Table 6 U.S. autoimmune disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 7 U.S. autoimmune disease diagnostics market, by region, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 U.S. autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
Table 3 U.S. autoimmune disease diagnostics market, by test type, 2018 - 2030 (USD Million)
Table 4 U.S. systemic autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
Table 5 U.S. localized autoimmune disease diagnostics market, by type, 2018 - 2030 (USD Million)
Table 6 U.S. autoimmune disease diagnostics market, by end-use, 2018 - 2030 (USD Million)
Table 7 U.S. autoimmune disease diagnostics market, by region, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. Autoimmune disease diagnostics market: market outlook
Fig. 9 U.S. Autoimmune disease diagnostics competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. Autoimmune disease diagnostics market driver impact
Fig. 14 U.S. Autoimmune disease diagnostics market restraint impact
Fig. 15 U.S. Autoimmune disease diagnostics market: Type movement analysis
Fig. 16 U.S. Autoimmune disease diagnostics market: Type outlook and key takeaways
Fig. 17 Systemic autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Rheumatoid arthritis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Ankylosing spondylitis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Systemic lupus erythematosus (SLE) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Localized autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Multiple sclerosis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Type 1 diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Hashimoto's Thyroiditis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Idiopathic thrombocytopenic purpura market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 U.S. Autoimmune disease diagnostics Market: Treatment movement Analysis
Fig. 29 U.S. Autoimmune disease diagnostics market: Treatment outlook and key takeaways
Fig. 30 Surgical ablation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Percutaneous ablation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Laparoscopic ablation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 U.S. Autoimmune disease diagnostics market: application movement analysis
Fig. 34 U.S. Autoimmune disease diagnostics market: application outlook and key takeaways
Fig. 35 Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Other market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 U.S. Autoimmune disease diagnostics market: regional movement analysis
Fig. 42 U.S. Autoimmune disease diagnostics market: regional outlook and key takeaways
Fig. 43 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 U.S. Autoimmune disease diagnostics market: market outlook
Fig. 9 U.S. Autoimmune disease diagnostics competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 U.S. Autoimmune disease diagnostics market driver impact
Fig. 14 U.S. Autoimmune disease diagnostics market restraint impact
Fig. 15 U.S. Autoimmune disease diagnostics market: Type movement analysis
Fig. 16 U.S. Autoimmune disease diagnostics market: Type outlook and key takeaways
Fig. 17 Systemic autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Rheumatoid arthritis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Ankylosing spondylitis diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Systemic lupus erythematosus (SLE) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Localized autoimmune disease diagnostics market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Multiple sclerosis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Type 1 diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Hashimoto's Thyroiditis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Idiopathic thrombocytopenic purpura market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 U.S. Autoimmune disease diagnostics Market: Treatment movement Analysis
Fig. 29 U.S. Autoimmune disease diagnostics market: Treatment outlook and key takeaways
Fig. 30 Surgical ablation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Percutaneous ablation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Laparoscopic ablation market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 U.S. Autoimmune disease diagnostics market: application movement analysis
Fig. 34 U.S. Autoimmune disease diagnostics market: application outlook and key takeaways
Fig. 35 Kidney cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Liver cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Breast cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Lung cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Prostate cancer market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Other market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 U.S. Autoimmune disease diagnostics market: regional movement analysis
Fig. 42 U.S. Autoimmune disease diagnostics market: regional outlook and key takeaways
Fig. 43 West market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Midwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Northeast market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 46 Southwest market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 47 Southeast market estimates and forecasts, 2018 - 2030 (USD Million)
